Effect of mutation order on myeloproliferative neoplasms - Reply

New England Journal of Medicine

Volumn 372, Issue 19, 2015, Pages 1865-1866

  Kent, David G ^a   Ortmann, Christina A ^a   Green, Anthony R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; DNA BINDING PROTEIN; ONCOPROTEIN;

CELL EXPANSION; CLONE; ERYTHROID CELL; GENE; GENE MUTATION; HEMATOPOIETIC STEM CELL; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; JAK2 GENE; LETTER; MYELOPROLIFERATIVE NEOPLASM; POLYCYTHEMIA VERA; PRIORITY JOURNAL; TET2 GENE; GENETICS; MUTATION; MYELOPROLIFERATIVE DISORDER; PHYSIOLOGY;

DNA-BINDING PROTEINS; HEMATOPOIETIC STEM CELLS; HUMANS; JANUS KINASE 2; MUTATION; MYELOPROLIFERATIVE DISORDERS; PROTO-ONCOGENE PROTEINS;

EID: 84928958369     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1503143     Document Type: Letter

References (2)

1. Dupont S, Massé A, James C, et al. The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 2007;110:1013-21.
2. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360:2289-301.